SCHEMBL13046839

SCHEMBL13046839

CN(C)CCn1ccc2c(NC(=O)c3cc(Cl)ccc3Cl)cccc2c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
P2RX7 Q99572 1/20 0.46
GRM2 Q14416 2/20 0.43
NR4A2 P43354 1/20 0.43
HTT P42858 1/20 0.42
MEN1 O00255 1/20 0.41
CLK1 P49759 1/20 0.41
KMT2A Q03164 1/20 0.41
HTR6 P50406 1/20 0.39
RORC P51449 1/20 0.39
PTGES O14684 1/20 0.39
POLB P06746 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13046838 0.92 KDM4E (0.53) ALDH1A1SMN1; SMN2KDM4EHPGDNPSR1
SCHEMBL13046900 0.91 P2RX7 (0.45) ALDH1A1SMN1; SMN2KDM4EHPGDNPSR1
SCHEMBL13046901 0.91 MAPT (0.43) ALDH1A1SMN1; SMN2KDM4EHPGDNPSR1
SCHEMBL13046877 0.89 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2KDM4EHPGDNPSR1
SCHEMBL13046836 0.89 HPGD (0.52) ALDH1A1SMN1; SMN2KDM4EHPGDNPSR1
SCHEMBL13046888 0.85 GRM2 (0.46) ALDH1A1SMN1; SMN2KDM4EHPGDNPSR1
SCHEMBL13046843 0.85 P2RX7 (0.44) SMN1; SMN2NPSR1P2RX7GRM2HTR6
SCHEMBL13047435 0.84 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KDM4EHPGDNPSR1
SCHEMBL13047354 0.83 P2RX7 (0.51) ALDH1A1HPGDP2RX7GRM2MEN1
SCHEMBL13046905 0.83 PARP1 (0.42) ALDH1A1KDM4EHPGDP2RX7GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546579-B2 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof EVOTEC (US) INC. (US) 2013-10-01 US disclosed
US-8546579-B2 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof EVOTEC (US) INC. (US) 2013-10-01 US disclosed
US-20100292235-A1 Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof SECOND GENOME, INC. 2010-11-18 US disclosed
US-20100292235-A1 Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof SECOND GENOME, INC. 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292235-A1 Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof P2RX7, P2RX3, P2RX2 ALDH1A1 3640/4885SMN1; SMN2 4369/4885KDM4E 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.